GLP-1 and Blood Pressure: Biomarker Insights

Last reviewed: May 30, 2026

Last updated: May 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists do not uniformly increase blood pressure; in fact, clinical trials show modest blood pressure reductions in many patients, though responses vary significantly. Individual metabolic factors, baseline cardiovascular health, and genetic predispositions influence how each person's body responds to GLP-1 therapy.

For patients considering compounded GLP-1 medications, understanding your unique cardiovascular profile and genetic context is essential. PlexusDx supports precision wellness by combining clinical evidence with biomarker and genetic insights, helping you and your provider evaluate whether GLP-1 therapy aligns with your individual health goals and cardiovascular status.

Blood Pressure Trends in GLP-1 Clinical Trials

Large randomized controlled trials of GLP-1 receptor agonists demonstrate systolic blood pressure reductions averaging 2–4 mmHg in patients with and without type 2 diabetes. The LEADER trial (liraglutide) and SUSTAIN-6 trial (semaglutide) both showed modest but statistically significant reductions in cardiovascular events, partly attributed to blood pressure and weight improvements.

However, individual responses are heterogeneous. Some patients experience no change, while others report reductions of 10–15 mmHg or greater. Weight loss magnitude, baseline hypertension status, and concurrent antihypertensive medication use all influence blood pressure outcomes during GLP-1 therapy.

Key Cardiovascular Biomarkers and GLP-1 Response Patterns

Individual baseline cardiovascular biomarkers—including blood pressure, heart rate, lipid profiles, and inflammatory markers—help predict how a patient may respond to GLP-1 therapy. Understanding these factors before starting treatment supports more tailored and safer therapy selection.

Biomarker/Factor	Clinical Relevance to GLP-1 BP Response
Baseline Systolic BP	Hypertensive patients may experience greater absolute BP reductions than normotensive individuals; those on multiple antihypertensive agents require closer monitoring.
BMI and Weight Status	Patients with higher baseline BMI often achieve greater weight loss, which correlates with more pronounced blood pressure reductions during GLP-1 therapy.
Heart Rate Response	GLP-1 drugs may increase resting heart rate by 2–4 bpm; this effect varies by individual and is generally considered benign, though it warrants monitoring in susceptible patients.
Renal Function and Proteinuria	GLP-1 therapy reduces proteinuria and slows renal disease progression; improved kidney function supports overall cardiovascular stability and blood pressure regulation.

Genetic Predispositions and Individual GLP-1 Receptor Sensitivity

Genetic variation in the GLP-1 receptor (GLP1R) and related metabolic pathways influences how efficiently your cells respond to GLP-1 therapy. Variants in genes like GLP1R rs6923761 and MC4R rs17782313 may modulate appetite regulation, weight loss, and blood pressure responses to GLP-1 medications.

The Precision Peptide Genetic Test examines key predispositions in GLP-1 and related metabolic pathways. Understanding these genetic factors may help provide context for why two patients on the same GLP-1 dose may experience different blood pressure and metabolic outcomes, supporting more informed conversations with your healthcare provider.

Who Should Monitor Blood Pressure Closely During GLP-1 Therapy

Patients with existing hypertension, particularly those on multiple antihypertensive medications, require closer blood pressure monitoring when initiating or adjusting GLP-1 doses. Rapid weight loss may enhance the effects of existing medications, potentially requiring dose adjustments to prevent hypotension.

Individuals with a history of diabetic kidney disease, cardiovascular disease, or orthostatic hypotension should discuss GLP-1 therapy with a qualified healthcare provider before starting. Your medical history, current medications, and cardiovascular biomarkers all inform whether GLP-1 is appropriate and what monitoring frequency is needed.

How PlexusDx Supports a More Personalized Approach

PlexusDx genetic and biomarker insights may help provide context for your individual blood pressure response to GLP-1 therapy. The Precision Peptide Genetic Test reveals predispositions in key GLP-1 receptor pathways and metabolic genes, including GLP1R rs6923761, MC4R rs17782313, and FTO rs9939609, which influence weight loss magnitude and metabolic regulation. This genetic information should be interpreted with a qualified healthcare provider as part of a comprehensive assessment.

The Precision Peptide Genetic Test does not predict your exact blood pressure response to a specific GLP-1 medication. Rather, it identifies genetic predispositions in peptide pathways that correlate with variations in weight loss, appetite regulation, and metabolic outcomes. These predispositions may inform why some patients achieve greater therapeutic benefit than others, but individual response remains influenced by many environmental, behavioral, and clinical factors.

Combining your genetic predisposition data with your current biomarkers—baseline blood pressure, BMI, cardiovascular history, and kidney function—can support a more personalized conversation with your provider about GLP-1 therapy selection, dosing strategy, and monitoring plan. PlexusDx compounded semaglutide and tirzepatide options are available at multiple dose strengths, allowing providers to tailor initiation and titration protocols to your individual profile.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

GLP-1 and Blood Pressure: Biomarker Insights | PlexusDx